Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals (Nasdaq: AVIR) has announced that its CEO, Jean-Pierre Sommadossi, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 3:05 p.m. ET. A live webcast will be available on the company's website, with a replay offered for 90 days post-event. Atea focuses on developing oral therapies targeting life-threatening viral infections, including SARS-CoV-2, dengue virus, hepatitis C, and respiratory syncytial virus using a proprietary nucleotide prodrug platform.
Atea Pharmaceuticals (NASDAQ: AVIR) announced the termination of its collaboration with Roche for the development of AT-527 for COVID-19, effective February 10, 2022. This change allows Atea to regain full rights for the clinical development and commercialization of AT-527 globally. Atea has $839.7 million in cash, ensuring a runway through 2023. The company is proceeding with the Phase 3 MORNINGSKY trial, expecting results in the second half of 2022, thereby enhancing its autonomy to bring AT-527 to market.
Atea Pharmaceuticals (AVIR) announced key updates in its third quarter 2021 report. A protocol amendment for the Phase 3 MORNINGSKY trial will refine the patient population to unvaccinated high-risk individuals and increase the dosage of AT-527 to 1,100 mg BID. Results from the Phase 2 MOONSONG trial indicated rapid antiviral activity against COVID-19, especially in high-risk patients. Financially, Atea reported collaboration revenue of $32.8 million and a net loss of $28.2 million for the quarter, a significant increase from the prior year's loss. Cash reserves stand at $839.7 million.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a live conference call on November 11, 2021, at 4:30 p.m. ET to report its third quarter financial results for the period ending September 30, 2021. The company focuses on developing oral therapeutics for life-threatening viral diseases, leveraging a proprietary nucleotide prodrug platform. The call will include a clinical and corporate update, with access details available on Atea's website. A recorded webcast will be archived approximately two hours after the event.
Atea Pharmaceuticals reported that the Phase 2 MOONSONG trial for AT-527 did not meet its primary endpoint for outpatients with mild or moderate COVID-19. The study revealed a significant reduction in viral load (0.5 log10) in high-risk patients at specific dosages (550 mg and 1,100 mg BID) compared to placebo. Following these results, Atea and Roche are considering modifications to the Phase 3 MORNINGSKY trial protocol. AT-527 has demonstrated a favorable safety profile, with no serious adverse effects noted.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) has announced upcoming presentations at the ISIRV-WHO virtual conference, taking place from October 19 to 21, 2021. The company will present analyses and interim results from the AT-527 COVID-19 clinical trial program, focusing on a Phase 2 study involving high-risk hospitalized patients and findings from a bronchoalveolar lavage study in healthy volunteers. Atea is collaborating with Roche to advance AT-527 as an oral antiviral treatment for COVID-19, aiming to provide a critical at-home treatment option as the virus becomes endemic.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on October 5, 2021, at 9:30 a.m. ET. A live webcast will be available on the company's website for 90 days post-event. Atea focuses on developing oral therapies for life-threatening viral infections, including SARS-CoV-2, dengue virus, HCV, and RSV, utilizing its proprietary nucleotide prodrug platform to address unmet medical needs.
Atea Pharmaceuticals announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 2:00 p.m. ET. CEO Jean-Pierre Sommadossi and the management team will engage in a fireside chat. A live webcast will be accessible on Atea's website, with a replay available for 90 days post-event. Atea focuses on developing oral therapies for severe viral diseases, leveraging its proprietary nucleotide prodrug platform to target viruses like SARS-CoV-2 and HCV.
Atea Pharmaceuticals (AVIR) announced promising data for its dengue virus treatment candidate, AT-752, published in Antimicrobial Agents and Chemotherapy. The research shows AT-752 has potent in vitro and in vivo activity against multiple dengue virus serotypes, reducing viremia and improving survival rates in animal models. The Phase 1a clinical trial demonstrated good tolerance with no serious adverse events at doses up to 1500 mg. Dengue fever is a significant global health issue, with 400 million infections annually, highlighting the urgency for effective antiviral treatments.
Atea Pharmaceuticals (AVIR) announced promising interim Phase 2 results for AT-527, a COVID-19 treatment, showing rapid viral load decrease in hospitalized patients. The active metabolite achieved target antiviral levels in lung fluid, critical for effective treatment. Collaboration with Roche continues, facilitating multiple ongoing clinical studies. Financially, Q2 2021 collaboration revenue reached $60.4 million, with a net income of $1.5 million, significantly improving from a loss in the previous year. Cash reserves stand at $816.5 million, reflecting strong financial backing for ongoing development.